FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	DC	20549

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL							
OMB Number: 3235-0287							
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Last) C/O AEI 200 BER (Street)	C/O AEROVATE THERAPEUTICS, INC. 200 BERKELEY STREET, FLOOR 18 Street) BOSTON MA 02116					2. Issuer Name and Ticker or Trading Symbol Aerovate Therapeutics, Inc. [AVTE] 3. Date of Earliest Transaction (Month/Day/Year) 4. If Amendment, Date of Original Filed (Month/Day/Year)						6. It	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below) See Remarks 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
					Day/Year) Execution Date, if any (Month/Day/Year) Transaction Code (Instr. 8) Disposed Of (D) (Instr. 3, 4 to 2)				ed (A) or tr. 3, 4 and 5	5. Amount of Securities Beneficially Owned Following Reported		Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of ndirect Beneficial Dwnership Instr. 4)			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)		4. Transa	uts, calls, warrants, 5. Number of Derivative E			uired, Disposed of, or Beneficis, options, convertible securities 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Am of Securities Underlying Der Security (Instr. 4)			d Amount ies g Derivative	8. Price of Derivative	9. Number of derivative Securities Beneficially Owned Following Reported		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
Stock				Code	v	(A)	(D)	Date Exercisab		Expiration Date	Title	Amount of Number of Shares		Transacti (Instr. 4)	ion(s)		
Option (Right to Buy)	\$2.144 ⁽¹⁾	04/02/2021		A ⁽²⁾		50,850 ⁽¹⁾		(3)	0	04/01/2031	Common Stock	50,850(1	\$0	50,850)(1)	D	
Stock Option (Right to Buy)	\$2.144 ⁽¹⁾	04/02/2021		A ⁽²⁾		98,676 ⁽¹⁾		(4)	0	04/01/2031	Common Stock	98,676(1	\$0	98,676	5 ⁽¹⁾	D	
Stock Option (Right to Buy)	\$14	06/29/2021		A		76,900		(5)	O	06/28/2031	Common Stock	76,900	\$0	76,90	00	D	

Explanation of Responses:

- 1. On June 22, 2021, the Issuer completed a one-for-3.1060103 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split.
- 2. This transaction occurred prior to the Issuer's initial public offering, and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3.
- 3. 25% of this option shall vest and become exercisable on March 22, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter.
- 4. 25% of this option shall vest and become exercisable on June 4, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter.
- 5. 25% of this option shall vest and become exercisable on June 29, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter.

Remarks:

Officer Title: Chief Financial Officer and Treasurer

/s/ George A. Eldridge

07/01/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.